In this first episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we embark on a journey into the world of MASH (metabolic dysfunction-associated steatohepatitis). Our experts will explain what MASH is and share their insights on the new MASH name, offering a glimpse into how it may help to reshape the landscape of liver disease screening, diagnosis, and management. Join us as we explore the MASH disease state and lay the foundation for future episodes focused on specific aspects of MASH screening and management.
Let’s dive into the world of MASH together. On the first episode of this series, please join experts Mazen Noureddin, MD, MHS (Transplant Hepatologist and Professor of Medicine at Houston Methodist Hospital), Amreen Dinani, MD, MSc (Hepatologist and Associate Professor of Medicine at Duke University) and Sonal Kumar, MD, MPH (Clinical Director of Hepatology and Gastroenterology at Weill Cornell Medical College), as they provide an overview of MASH (formerly called NASH). The experts will discuss the epidemiology and pathophysiology of MASH, including comorbidities, as well as the importance of recognizing MASH as a cardiometabolic disorder. The discussion will also explore the recent name change of the disease—from NASH to MASH—and how this may impact the landscape of screening, diagnosis, and management.
This program is intended for clinicians in the US only. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
Mazen Noureddin, MD, MHS
Transplant Hepatologist and Professor of Medicine
Houston Methodist Hospital
Houston, TX
Amreen Dinani, MD, MSc
Hepatologist and Associate Professor of Medicine
Duke University
Durham, NC
Sonal Kumar, MD, MPH
Clinical Director of Hepatology and Gastroenterology
Weill Cornell Medical College
New York, NY
Click here for full reference list
References
American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S52-S76.
Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020;3(4):e00112.
Cusi K, Budd J, Johnson E, Shubrook J. Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: What clinicians need to know. Diabetes Spectr. 2024;37(1):29-38.
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endocr Pract. 2022;28(5):528-562.
Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: Rationale, opportunities and challenges. Gut. 2020;69(10):1877-1884.
Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.
Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60.
Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598-607.
Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver fibrosis in non-alcoholic fatty liver disease: From liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne). 2021:8:615978.
Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669.
Liver Foundation. Accessed March 19, 2024. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-definition-prevalence
Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications-what the non-specialist needs to know. Diabetes Obes Metab. 2022;24(Suppl 2):3-14.
Ng CH, Lim WH, Hui Lim GE, et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(4):931-939.
Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: Updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649-1659.
Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells. 2020;9(4):1005.
Rinella M, Cryer DR, Articolo A, Fisher T, Schneider J, Nadolsky K. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol. 2022;22(1):335.
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: A targeted literature review. Expert Rev Gastroenterol Hepatol. 2021;15(11):1253-1266.
Schattenberg JM, Lazarus JV, Newsome PN, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227-1242.
Sherif ZA. Unmasking a stealth killer: The need for increased awareness of NASH. Dig Dis Sci. 2020;65(4):987-989.
Shroff H, VanWagner LB. Cardiovascular disease in nonalcoholic steatohepatitis: Screening and management. Curr Hepatol Rep. 2020;19(3):315-326.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347.